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Summary
To predict the prognosis of neuroblastoma patients and choose a better therapeutic protocol, we developed a cDNA
microarray carrying 5340 genes obtained from primary neuroblastomas and examined 136 tumor samples. We made a
probabilistic output statistical classifier that provided a high accuracy in prognosis prediction (89% at 5 years) and a
highly reliable method to validate it. Kaplan-Meier analysis indicated that the patients in an intermediate group defined by
existing markers are divided by microarray into two further groups with 5 year survivals for 36% and 89% of patients (p <
10−4), i.e., with unfavorably and favorably predicted neuroblastomas, respectively. According to these results, we devel-
oped a gene subset chip for a clinical tool, for which our classifier exhibited 88% prediction accuracy.S I G N I F I C A N C E
Neuroblastoma is an enigmatic tumor with heterogeneous clinical behaviors including maturation, regression, and growth. Despite
recent improvements in the cure rate of many pediatric tumors, the prognosis of advanced neuroblastoma is still poor. In addition,
it is usually difficult to predict the prognosis of the intermediate risk group in advanced stages without MYCN amplification. Through
our supervised machine learning and highly reliable statistical validation procedure with the 5 year prognosis of the patients, we
established a simple, low-cost microarray system carrying top-ranked genes, which exhibited high accuracy (88%) to predict the
neuroblastoma prognosis and is highly feasible as a clinical tool.Introduction
Neuroblastoma is one of the most common solid tumors in
children and originates from the sympathoadrenal lineage of
the neural crest (Bolande, 1974). Its clinical behaviors are
heterogeneous. The tumor, when developed in infants, fre-
quently regresses spontaneously by inducing differentiation
and/or programmed cell death. When developed in children
over 1 year of age, however, the tumor is often aggressive and
acquires resistance to intensive chemotherapy. Although re-
cent progress in therapeutic strategies against advanced neu-
roblastoma has improved patient survival, long-term outcomes
still remain very poor. Furthermore, part of neuroblastomas cat-
egorized to the intermediate group (stage 3 or 4 tumors that
possess a single copy of the MYCN gene) often recurs after
complete response to initial therapy. Such differences in the
final outcomes of the tumor are considered presumably attrib-
utable to differences in genetic and biological abnormalities,
which are reflected in the gene and protein expression profiles
of the tumor.CANCER CELL : APRIL 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INCThe prediction of cancer prognosis is one of the most urgent
demands to initiate the treatment of neuroblastoma. As ex-
pected from the natural course of neuroblastoma, patient age
at diagnosis (over or under 1 year of age) is an important prog-
nostic factor (Evans et al., 1971). Disease stage is also a pow-
erful indicator for neuroblastoma prognosis (Brodeur et al.,
1993). Moreover, recent advances in basic research have dis-
covered several molecular markers that are useful in clinical
practice, including amplification of the MYCN oncogene
(Schwab et al., 1983; Brodeur et al., 1984), DNA ploidy (Look
et al., 1984; Look et al., 1991), deletion of chromosome 1p
(Brodeur et al., 1988), and TrkA expression (Nakagawara et al.,
1992; Nakagawara et al., 1993). Other indicators also include
telomerase (Hiyama et al., 1995), CD44 (Favrot et al., 1993),
pleiotrophin (Nakagawara et al., 1995), N-cadherin (Shimono et
al., 2000), CDC10 (Nagata et al., 2000), and Fyn (Berwanger et
al., 2002). However, the combinations thereof still frequently fail
to predict patient outcome. In the post-genome sequence era,
therefore, the advent of new diagnostic tools has been ex-. DOI 10.1016/j.ccr.2005.03.019 337
A R T I C L Epected. Recently, the DNA microarray method, applied to com-
prehensively demonstrate expression profiles of primary neuro-
blastomas and cell lines, has already identified the following:
(1) differences in gene expression between favorable and unfa-
vorable subsets (Yamanaka et al., 2002; Berwanger et al.,
2002); and (2) differences in gene expression that occur during
retinoic acid-induced neuronal differentiation (Ueda, 2001).
However, a study to predict neuroblastoma prognosis with a
microarray using a large number of neuroblastoma samples
has never been reported. We have recently isolated 5500
genes from the cDNA libraries, which were generated from pri-
mary neuroblastomas, part of which has previously been re-
ported (Ohira et al., 2003a; Ohira et al., 2003b). In this study,
to identify genes strongly associated with neuroblastoma prog-
nosis and to apply them to make a really practical cDNA micro-
array for neuroblastoma diagnosis, we constructed an in-
house, ink-jet-printed cDNA microarray carrying 5340 genes
proper to neuroblastoma and applied it to analyze 136 sam-
ples. After selecting genes significantly related to patient prog-
nosis, we made a mini-chip carrying 200 top-ranked genes to
apply for the clinic.
There have been many attempts to predict cancer outcome
using microarray. A reliable prediction for outcomes of cancer
patients naturally demands its reproducibility, and it is quite
important to use sound and highly reliable statistical methodol-
ogies; a complete crossvalidation analysis without introducing
any information leakage and an independent test using new
samples are necessary. As Ntzani and Ioannidis (2003) pointed
out, however, such a careful methodology has often been ig-
nored in most microarray studies. We here developed a super-
vised classification method without any information leakage as
a statistic tool and demonstrated that the probabilistic output
of the analysis defines the molecular signature of neuro-
blastoma to predict its prognosis. Although the construction of
the statistical tool was based on one of the most reliable statis-
tical tests, we also consulted a validation test for an indepen-
dent experiment examining 50 samples (whose RNAs were
prepared in an independent laboratory) by using the mini-chip.
The high performance for the outcome prediction by the mini-
chip system suggests the high feasibility of developing a clin-
ical tool based on molecular signature.
Results
Neuroblastoma proper cDNA microarray
The whole scheme of our study is summarized in Figure 1. We
first constructed a neuroblastoma proper cDNA microarray
harboring the spots of 5340 genes on a slide glass by using a
ceramics-based ink-jet printing system (the 5340 genes sys-
tem). This in-house cDNA microarray appeared to have over-
come the previous problems caused by pin-spotting, e.g., un-
even quantity or shape of individual spots on an array. Ten
micrograms each of the total RNA extracted from 136 frozen
tissues of primary neuroblastomas were labeled with Cy3 dye.
As a common reference, the mixture of the total RNA obtained
from four neuroblastoma cell lines with a single copy of MYCN
(NB69, NBLS, SK-N-AS, and SH-SY5Y) was labeled with Cy5
dye.
We first evaluated the quality of our cDNA microarray, the
5340 genes system. The log Cy3/Cy5 fluorescence ratio of338each gene spot was normalized to eliminate intensity-depen-
dent biases. Since the 5340 genes array contains 260 dupli-
cated or multiplicated genes, the expression ratio of such a
duplicated gene was represented by the average of multiple
spots. Based on estimation performance for missing values
(see the Supplemental Data available with this article online)
and on reproduction variance of the duplicated genes, the
standard deviation for the log ratio of a single gene was suffi-
ciently small, ranging between about 0.2 and about 0.3 (Figure
S1A). The scatter plots of the log Cy3/Cy5 fluorescence ratio
between duplicated gene spots in the 136 experiments and
those between repeated experiments also indicated high re-
producibility of spotting and experiment (Figures S1B and
S1C). These suggest that the production of and experiments
by our cDNA microarray are highly reproducible.
Supervised classification
To develop a statistical tool that predicts the prognosis of a
new patient with neuroblastoma, we introduced a supervised
classification. In the development, we used 136 neuroblastomas,
randomly selected tumor samples from the neuroblastoma tis-
sue bank, consisting of 41 stage 1 tumors, 22 stage 2 tumors,
33 stage 3 tumors, 28 stage 4 tumors, and 12 stage 4s tumors.
The follow-up duration ranged between 3 and 241 months (me-
dian, 56 months, mean, 57.3 months) after diagnosis. The left
panel in Figure 2 compiles summary information of each sam-
ple, including survival time and important prognosis markers
(see Experimental Procedures for details). Since variations in
follow-up duration generated noises in the supervised classifi-
cation, we used patient outcome (dead or alive) at 5 years after
diagnosis as the target label to be predicted. Since the out-
comes of 40 of 136 samples were unknown at 5 years after
diagnosis, data for 96 remaining samples were used subse-
quently. When we were interested in short-term outcome pre-
diction, the target label was set at 2 years after diagnosis, for
which purpose 126 samples out of the 136 samples were used.
We constructed the weighted voting as a supervised classi-
fier after important genes were selected according to pairwise
F scores. To estimate the prediction accuracy for new data, we
consulted leave two out (LTO) analysis, which obtains almost
unbiased estimation of prediction accuracy for new data while
avoiding overestimation due to information leakage (Figure
S2A). Although it is known that the prediction accuracy of a
supervised classifier depends on the number of genes to be
used (Figure S3), the LTO procedure enables us to optimize it
without introducing information leakage, by using a sample left
out at the outer loop of the double-loop procedure (see Experi-
mental Procedures). The crossvalidation accuracy for the 5
year prognosis prediction was as high as 88.5% (sensitivity of
86.7% and specificity of 89.4%) (Table 1, “Whole cases”). In
the LTO analysis, we selected genes and constructed the cor-
responding classifier individually for the outcome prediction of
each sample. The average number of the selected genes, n,
was 30.7. If we applied the same procedure to the short-term
(2 year) prediction, the accuracy, sensitivity, and specificity
were 89.8%, 88.0%, and 90.2%, respectively (data not shown).
Construction of a probabilistic output
According to the LTO analysis, we can obtain weighted vote
values and the corresponding survival rates. After approximat-CANCER CELL : APRIL 2005
A R T I C L EFigure 1. Schematic diagram of this studying a nonlinear transformation from weighted vote values to the
survival rates, the transformation outputs the reliability of each
sample’s outcome prediction as a probabilistic output, poste-
rior probability. We suppose each posterior probability, a real
number between 0 and 1, corresponds to the expected 5 year
survival rate. The right upper panel of Figure 2 shows the pre-
dictions for the 136 samples as posterior probabilities. Most of
the samples alive at 5 years after diagnosis (blue mark) are
found to have posterior values near 1, while most of the dead
samples (red mark) have those near 0. It is known that it is
difficult to predict the prognosis of neuroblastoma patients of
the intermediate risk group (the type II subset: stage 3 or 4,
without amplification of MYCN), denoted by green area. The
posterior values are likely to take intermediate values near 0.5;
however, their binarization after being separated by threshold
0.5 shows good accordance with the actual outcome. Fre-
quencies of posterior values for alive and dead samples are
shown in the right middle panel. The rate of alive samples
among the whole samples, which denotes the actual survival
rate, is plotted against each posterior value in the right bottom
panel in Figure 2; this panel shows the good correspondence
between the posterior value and the survival rate.
Probabilistic outputs are considered to be advantageously
useful as compared with conventional binary outputs when
used in making a clinical assessment and may be considered
identical to them if establishing an appropriate threshold value.
The real-valued posterior can be used for categorization into
arbitrary number of groups. For example, dividing the posterior
values into three by setting thresholds 0.3 and 0.7, we obtain
three groups whose survival curves are significantly different
from each other; this tertiary categorization provides another
definition of intermediate risk group based only on expression
patterns (Figure S4).
Comparing the survival curves
Figure 3A shows survival curves for favorable and unfavorable
patients predicted by the classifier with a binary threshold (0.5).CANCER CELL : APRIL 2005The 5 year survival rate for the former (n = 98) was as good as
94%, while that for the latter (n = 38) was as poor as 33% (p <
10−5). When 70 sporadic neuroblastomas were evaluated after
excluding the tumors found by mass screening, the 5 year sur-
vival rate for the former (n = 40) was 85%, while that for the
latter (n = 30) was 20% (p < 10−5) (Figure 3B). To further evalu-
ate the efficiency of our system, we calculated the posterior
value for the intermediate subset of neuroblastoma (type II),
whose prognosis is usually difficult to predict. As shown in Fig-
ure 3C, the survival curves were significantly categorized into
two groups. The 5 year survival rate of patients who were pre-
dicted as favorable was 89%, while that for unfavorable pa-
tients was 36% (p = 0.000067). Since the age at diagnosis (R1
year) is currently used as a poor prognostic factor for the type
II tumors, we examined the ability of the classifier for the older
patients with type II tumors. Even for such patients whose
prognosis is difficult to predict, the survival rate (45%) of all 18
patients was divided solely by gene expression into the group
with favorable prognosis (n = 10; 73%) and that with poor out-
come (n = 8; 13%) (Figure 3D). In addition, if the intermediate
risk group was further separated into stage 3 tumor group and
stage 4 tumor group, the posterior value was significantly re-
lated to the survival, especially for stage 3 tumors (Figure S5).
These results suggest that the posterior value obtained by our
statistical analysis highly efficaciously allows the classification
of patient outcomes, even when the tumor is of the intermedi-
ate type.
We further compared our results to existing prognosis mark-
ers in Table 1 and found that the supervised microarray analy-
sis showed the best sensitivity-specificity balance among the
prognostic factors for predicting the outcome of neuro-
blastoma. When the classifier is combined with the age at diag-
nosis, the disease stage (stage 1, 2, or 4s versus stage 3 or 4)
and the MYCN amplification, accuracy, sensitivity, and speci-
ficity increased up to 95.8%, 93.3%, and 97.0%, respectively.
Although the currently used markers (age, stage, and MYCN)339
A R T I C L EFigure 2. Posterior probability of survival at 5
years
Posterior probability of survival at 5 years for 136
training data samples, output by the leave two
out (LTO) crossvalidation without any informa-
tion leakage. Left panel: Neuroblastoma sam-
ples. A red or blue horizontal line denotes sur-
vival period after diagnosis for a dead or alive
patient, respectively. Red and blue marks de-
note various clinical properties of patients; see
text below the panel for detailed explanation.
Background colors show groups determined by
stage and MYCN amplification status: red, type
III, with MYCN amplification; green, type II, with
single copy of MYCN at unfavorable stage (3 or
4); and blue, type I, with single copy of MYCN
and at favorable stage (1, 2, or 4s). Right upper
panel: The LTO crossvalidated prediction (pos-
terior) for each patient; a red or a blue mark
denotes that the patient is dead or alive at 5
years, respectively. Right middle panel: Cumu-
lative smooth histogram of posterior probabili-
ties for patients of dead (red), alive (blue), and
unknown (white) at 5 years after diagnosis. Right
lower panel: The horizontal and vertical axes
denote the posterior and the empirical prob-
ability of 5 year survival, i.e., the ratio of the
smooth histogram values between dead and
alive patients, shown in the middle panel,
respectively. Because the border between
dead and alive samples is close to the white
broken line (x = y), the posterior can be re-
garded as a 5 year survival chance rate.340 CANCER CELL : APRIL 2005
A R T I C L ETable 1. Accuracy of each marker for prognosis prediction (5 years after diagnosis)
Whole cases Sporadic cases Intermediate and old agea
n accuracy sensitivity specificity n accuracy n accuracy
Microarray classifier 136 89% 87% 89% 56 82% 14 86%
Age (less than 1 year old) 136 81% 83% 80% 56 71% 14 64%
Stages (1, 2, and 4s) 136 83% 97% 77% 56 84% 14 64%
Shimada classification 62 87% 78% 89% 25 72% (n < 10) —
(unfavorable)
Hyperdiploidy (aneuploidy) 62 72% 67% 73% 27 56% (n < 10) —
MYCN amplification 136 89% 67% 99% 56 80% 14 36%
Microarray + age + stages 136 96% 93% 97% 56 93% 14 86%
+ MYCN*
Sensitivity/specificity is the rate of unfavorably/favorably predicted samples, i.e., LTO posterior <0.5/>0.5, among actually unfavorable/favorable samples. Microarray
classifier, supervised classification based on the microarray data. *By this classifier, all patients with the MYCN amplification are predicted as unfavorable, and all
patients with a single copy of MYCN and at stage 1, 2, or 4s are predicted as favorable. In the remaining intermediate samples (with a single copy of MYCN and at
stage 3 or 4), the patients with age <1 year are predicted as favorable, and the microarray predictions are applied for those with age >1 year.
aAge at diagnosis >1 year.Figure 3. Disease-free survival of patients who were stratified based on the
gene expression patterns
For each of the four figures, whole objective patients (green) are divided
into favorable (blue) or unfavorable (red) based on the posterior values
with threshold 0.5, which are calculated from gene expression patterns,
and statistical features of their survival times are denoted by the Kaplan-
Meier survival curves. The differences of the survival curves between the
favorable (blue) and unfavorable (red) groups are evaluated by p values
of the log rank test.
A and B: Survival analysis of whole and sporadic patients, respectively,
divided by the supervised classifier based on microarray data.
C and D: Survival analysis of patients in the intermediate risk group with
different definitions, divided by the supervised classifier. The intermediate
risk group shown in (C) is defined as MYCN single and stage 3 or 4 (type
II), and that in (D) is defined as MYCN single, stage 3 or 4, and older than
1 year of age.CANCER CELL : APRIL 2005also showed good potential to predict generally but less than
the microarray, these exhibited only 64% accuracy of predic-
tion for the type II tumors with R1 year of age (Table 1). To-
gether with the results of survival analysis, the microarray clas-
sifier is revealed to be a powerful predictor to classify such
group of neuroblastomas (86% accuracy; Table 1).
Practical application of 200 cDNAs microarray
and independent test
For the practical use in the clinic, a cDNA microarray system
that contains cDNA spots of a relatively small number and
hence is easy to treat is expected. According to our gene se-
lection based on the pairwise F score, the numbers of genes
that were appropriate for the 5 year and 2 year prognosis pre-
diction for all available samples were 10 and 70, respectively.
In order for the system to reserve the applicability to short-term
and long-term outcome prediction simultaneously, we selected
200 top-ranked genes according to the pairwise F scores in
the 2 year prediction, because the 2 year prediction required
larger variety of genes, and then made a smaller cDNA micro-
array system carrying the 200 genes. The newly designed
microarray system (the mini-chip system) was evaluated by be-
ing hybridized with 5 g total RNA obtained from 50 indepen-
dent test samples. To preserve the independence of experi-
mental procedure, these RNAs were prepared and hybridized
in a different laboratory from the original experiments of 136
samples with the 5340 genes system (see Experimental Pro-
cedures). Although the weight values in the weighted voting
classifier were determined by the 5340 genes system without
any information leakage from the 50 independent samples, the
result was as good as that obtained by the 5340 cDNA micro-
array analysis (90% [45/50] for 2 year, and 87.8% [43/50] for 5
year prognosis prediction; Figure 4B). This test validated not
only the prediction robustness of our classifier constructed by
the 5340 genes system, but also the construction procedure of
the mini-chip system according to our gene selection based on
pairwise F scores. When we reconstructed another supervised
classifier by applying the LTO analysis to the 50 samples mea-
sured by the mini-chip system, the accuracy of the 5 year pre-
diction was 91.8% (45/49) (Figure 4C). These results suggest341
A R T I C L EFigure 4. Posterior probability of survival at 5
years for test samples
Posterior probability of survival at 5 years for 50
independent test samples measured by newly
developed 200 genes chip (the mini-chip sys-
tem). Left panel: Neuroblastoma samples; see
also Figure 2 legend. Center panel: Prediction
results when the supervised classifier con-
structed from 96 training samples is applied to
the 50 independent samples (independent test
for the classifier’s reproducibility). Right panel:
LTO crossvalidation analysis using the new 50
samples (test for the procedure’s reproduci-
bility). Both tests do not introduce any informa-
tion leakage. Lower panels: Smooth histograms
of posterior probabilities for dead (red) and
alive (blue) patients.three things. (1) The supervised classifier obtained by the sta-
tistical analysis by the 5340 genes system is reproducible even
if it is applied to the data measured by the reduced 200 genes
system. Note that the 50 samples were completely new data
for the classifier in this case. (2) Our procedure to construct
a supervised classifier according to the LTO analysis is also
reproducible, because the same procedure was successful in
making another classifier with a high prediction accuracy when
applied to the data taken by the mini-chip system. (3) A simple,
low-cost microarray system, the mini-chip system, is highly
feasible for predicting the prognosis of neuroblastoma.
Genes selected for prognosis prediction
To assess the relationship between the clinically defined sub-
sets of neuroblastoma and the expression of 70 genes that
were selected as top scored with 2 year prognosis according to
the pairwise F score, we conducted an unsupervised clustering
analysis (Figure 5). As expected, part of the type II (intermedi-
ate) tumors of patients with a poor prognosis showed an ex-
pression pattern that was similar to that of the type III (unfavor-
able) tumors, and many of them died. On the other hand,
expression profiles of the remaining type II tumors seemed to
be heterogeneous similarly to those of the type I (favorable)342tumors with a good outcome. Most of the tumors with highly
expressed TrkA and hyperdiploidy, as well as tumors detected
by mass screening, were included in the latter group. Table 2
shows a list of 41 genes that corresponded to the 70 top-
scored genes and their p and q values (Storey and Tibshirani,
2003) in the log rank test, since we found that several genes
were duplicated in the selected 70 genes. Based on the above
clustering, these genes were categorized into two groups
(group F and group UF; the gene groups strongly correlated
with favorable and unfavorable prognosis, respectively) (Figure
5 and Table 2).
The genes in group F tended to show high levels of expres-
sion in the type I tumors, while those in group UF were highly
expressed in the type III tumors. The former contained genes
that were related to neuronal differentiation (tubulin α, periph-
erin, neuromodulin [GAP43], and HMP19) and genes that were
related to catecholamine metabolism (dopa decarboxylase
[DDC], dopamine β-hydroxylase [DBH], and tyrosine hydrox-
ylase [TH]). On the other hand, the latter involved many mem-
bers of genes that are related to protein synthesis (ribosomal
protein genes such as RPL18A, RPLP0, RPL5, RPL4, and
RPL7A as well as translation initiation and elongation factor
genes EEF1G and EIF3S5) and genes that are related to me-CANCER CELL : APRIL 2005
A R T I C L EFigure 5. Expression profiles of 70 genes selected for predicting neuroblastoma prognosis at 2 years
Note that 10 genes for predicting prognosis at 5 years are also included in the 70 genes. The left and lower trees depict hierarchical clustering of the 136
neuroblastoma samples and the 70 genes selected in the present study, respectively. In the left tree, blue, green, and red colors denote “MYCN single
and stage 1, 2 or 4s tumor” (type I, favorable), “MYCN single and stage 3, 4 tumor” (type II, intermediate), and “MYCN amplified tumor” (type III,
unfavorable), respectively. The blue and red colors in the expression matrix show the high and low expression, respectively. A gene showing high expression
level likely for unfavorable samples belongs to the group “UF” (red subtree in the lower tree), while one showing high expression likely for favorable samples
belongs to the group “F” (blue subtree in the lower tree).tabolism (enolase 1 [ENO1] and transketolase [TKT]). The top
10 genes selected for the 5 year outcome prediction were
RPL18A, ENO1, EEF1G, TUBA3, GNB2L1, ARHGEF7, GCC2,
DDX1 (duplicated), and PRPH. The MYCN gene was also a
member of 70 genes (group UF) as expected; however, it wasCANCER CELL : APRIL 2005outside of the top 10 genes for the 5 year label. Instead, DDX1,
which is frequently coamplified with MYCN on chromosome
2p24, was a member of the top 10 genes (UF group) for both
of the 2 year and 5 year labels. Confirmation of the differential
expression of the selected genes was further conducted by343
A R T I C L ETable 2. Top-ranked genes used for prediction of 2 year and 5 year prognosis of neuroblastoma
Spot name Accession number Gene code Chromosome map Pattern Log rank p q value
F group
Nbla11606 NM_006009 TUBA3 12q13.12 F > UF 0 0.000674
Nbla00890 NM_003899 ARHGEF7 13q34 F > UF 0.000001 0.000743
Nbla00260 NM_006082 K-ALPHA-1 12q13.12 F > UF 0.000003 0.000926
Nbla21891 U87309 VPS41 7p14.1 F > UF 0.000006 0.001096
Nbla03873 NM_006054 RTN3 11q13.1 F > UF 0.00001 0.001282
Nbla11788 NM_006262 PRPH 12q13.12 F > UF 0.000017 0.001522
Nbla10093 NM_000183 HADHB 2p23.3 F > UF 0.000018 0.001541
Nbla22572 NM_000790 DDC 7p12.2 F > UF 0.000035 0.00213
Nbla21270 NM_001915 CYB561 17q23.3 F > UF 0.00016 0.00495
gene071 NM_000360 TH 11p15.5 F > UF 0.000787 0.012173
Nbla03499 NM_002074 GNB1 1p36.33 F > UF 0.000795 0.012237
Nbla04181 AK55112 AK55112 5q13.2 F > UF 0.001425 0.017462
Nbla00487 AB075512 C6orf134 6p21.33 F > UF 0.002751 0.025273
Nbla00269 NM_000787 DBH 9q34.2 F > UF 0.00362 0.030407
Nbla22531 NM_002045 GAP43 3q13.31 F > UF 0.004394 0.034175
Nbla22156 NM_014944 CLSTN1 1p36.22 F > UF 0.005233 0.038274
Nbla00578 NM_006818 AF1Q 1q21.3 F > UF 0.009397 0.05354
Nbla00217 NM_032638 GATA2 3q21.3 F > UF 0.010245 0.056301
Nbla21394 NM_000743 CHRNA3 15q25.1 F > UF 0.072464 0.162629
Nbla11993 NM_015980 HMP19 5q35.2 F > UF 0.204274 0.282486
UF group
Nbla00214 NM_000980 RPL18A 19p13.11 F < UF 0.000002 0.001107
Nbla00013 NM_006098 GNB2L1 5q35.3 F < UF 0.000006 0.001051
Nbla11459 NM_004939 DDX1 2p24.3 F < UF 0.000024 0.001795
Nbla11148 NM_001002 RPLP0 12q24.23 F < UF 0.000049 0.002549
Nbla00332 NM_001404 EEF1G 11q12.3 F < UF 0.000055 0.002696
Nbla10395 NM_002593 PCOLCE 7q22.1 F < UF 0.000164 0.005009
Nbla03286 NM_020198 GK001 17q23.3 F < UF 0.000175 0.005204
Nbla23163 NM_003754 EIF3S5 11p15.4 F < UF 0.000341 0.007105
Nbla10579 NM_181453 GCC2 2q12.3 F < UF 0.000962 0.01407
Nbla00359 NM_003550 MAD1L1 7p22.3 F < UF 0.00112 0.01525
gene052-1 NM_005378 MYCN 2p24.3 F < UF 0.001253 0.016367
Nbla03925 NM_002295 LAMR1 3p22.2 F < UF 0.001773 0.01931
Nbla23424 NM_001404 EEF1G 11q12.3 F < UF 0.003579 0.030326
Nbla22554 NM_000687 AHCY 20q11.22 F < UF 0.003946 0.032409
gene056 NM_000546 TP53 17p13.1 F < UF 0.004087 0.032829
Nbla10873 NM_005762 TRIM28 19q13.43 F < UF 0.004984 0.037476
Nbla00501 NM_000969 RPL5 1p22.1 F < UF 0.005786 0.04012
Nbla10302 NM_001428 ENO1 1p36.23 F < UF 0.007702 0.048179
Nbla04200 NM_000968 RPL4 15q22.31 F < UF 0.04097 0.120453
Nbla03836 NM_000972 RPL7A 9q34.2 F < UF 0.048031 0.132345
Nbla00781 NM_001064 TKT 3p21.1 F < UF 0.048075 0.132342
Although 70 clones were selected as important genes for the supervised classifier, duplicated and multiplicated clones are omitted in this table. The 41 genes are
classified into two groups, “F > UF” and “F < UF,” when the expression in favorable samples is higher than that in unfavorable samples, and vice versa, respectively.
In each group, genes are sorted by log rank p values. The log rank p value for each gene was calculated by comparing survival curves of two patient groups, in which
the expression of the gene is higher and lower, respectively, than the median over the samples. A “q value” of a gene denotes the estimated false discovery rate among
the genes whose p value is the same or smaller than that of the gene, and is a p-like value while incorporating multiplicity of the statistical test.using representative 16 favorable and 16 unfavorable tumor
samples that were independent of the 136 samples used in the
present analysis, by semiquantitative RT-PCR (Figure S6; refer
also to Ohira et al., 2003a). We also conducted immunohisto-
chemical analysis for peripherin antibody using tissue sections
prepared from primary neuroblastoma with favorable and unfa-
vorable histology, since peripherin gene is a member of the top
10 genes for both 2 year and 5 year outcome prediction (Table
2). Peripherin protein was positively detected in the cytoplasm
of neuroblastic cells as well as neuritis in all three favorable
histology tumors (Figure S7, FH&NA). Two unfavorable histol-
ogy tumors with poorly differentiated subtype, regardless of
MYCN status, showed sporadic staining (less than 20% of the344favorable histology tumor) for peripherin protein in neurites.
Peripherin was completely negative in the unfavorable histol-
ogy tumor of undifferentiated subtype (Figure S7, UF&NA).
These results indicate the reliability of our gene selection. In
the log rank test, p values of 18 of 20 genes in group F and of
all 21 genes in group UF were less than 0.05 (Table 2), indicat-
ing that these 39 genes can be independent prognostic factors
for primary neuroblastomas.
Discussion
Our study has disclosed the molecular signature of neuro-
blastoma that predicts patient outcomes by using RNA ob-CANCER CELL : APRIL 2005
A R T I C L Etained from 136 primary neuroblastomas. The highly reliable
statistical analysis by using a neuroblastoma proper cDNA
microarray harboring 5340 genes based on an electrically con-
trolled ceramics-based ink-jet method led us to design a cDNA
microarray system harboring 200 genes, which is applicable to
short-term (2 year) and long-term (5 year) prognosis predic-
tions for neuroblastoma.
Our study demonstrated that the supervised classifier pro-
duced by the 5340 genes system provided a high accuracy
(88.5%) for the 5 year outcome prediction, with a good balance
between sensitivity (86.7%) and specificity (89.4%). Although
age at diagnosis, disease stage, MYCN amplification, and pa-
tients found by mass screening have been useful prognostic
markers currently used at the bedside, most of them have
either high sensitivity or high specificity (Table 1). The microar-
ray analysis showed the best sensitivity-specificity balance
among the prognostic factors for predicting the outcome of
neuroblastoma. When the classifier is combined with the age
at diagnosis, the disease stage (stage 1, 2, or 4s versus stage
3 or 4) and the MYCN amplification, accuracy, sensitivity, and
specificity increased up to 95.8%, 93.3%, and 97.0%, respec-
tively. Furthermore, the intermediate subset of neuroblastomas
(type II), for which a long-term prognosis is usually difficult to
make, was also categorized by microarray analysis into groups
of patients with a favorable prognosis and those with an unfa-
vorable prognosis. These successful results led us to produce
a more practical tool at the bedside, the mini-chip system,
whose accuracy, sensitivity, and specificity were 87.8%, 76.5%,
and 93.8%, respectively, when the classifier constructed by the
5340 genes system was applied to 50 independent samples
measured by the mini-chip system, and were 91.8%, 82.4%
and 96.9%, respectively, when another classifier was con-
structed by applying the LTO procedure to the same data
(Figure 4).
It is well recognized now that gene expression analyses for
cancer prognosis prediction should pay close attention to the
reproducibility of obtained results. A complete crossvalidation
analysis without introducing any information leakage and an
independent test using new samples are necessary. Although
the determination of the appropriate number of genes used in
supervised classifiers should be included in the validation pro-
cedure, it has often been ignored in most microarray studies.
van ’t Veer et al. (2002) applied the supervised classification to
the breast cancer gene signature, which is predictive of a short
interval to distant metastases in 78 patients who were initially
devoid of local lymph node metastasis. Although their cross-
validation analysis without the validation of the number of
genes correctly predicted the actual outcome of disease for 63
of 78 patients (80.7%), the accuracy was worse when a com-
plete validation was applied (73.1%). This difference suggests
that even small information leakage may lead to overestimation
of the accuracy. Beer et al. (2002) applied the supervised clas-
sification to the outcome prediction of lung adenocarcinoma.
Their statistical analysis was complete without any information
leakage. They did not report the prediction accuracy, but we
estimated the accuracy to be about 70% from the data in their
paper and found that the prediction by their supervised classi-
fier was not very superior to that by existing prognosis mark-
ers. Iizuka et al. (2003) applied the supervised classificationCANCER CELL : APRIL 2005to the prediction of intrahepatic recurrence within 1 year after
curative surgery for hepatocellular carcinoma patients. Al-
though their predictor showed sufficiently high accuracy in an
independent test with 27 samples, their crossvalidation pro-
cedure excluded the validation of the determination process of
the number of optimum genes (steps 5 and 6 in their algo-
rithm). The high crossvalidation accuracy of 100% may be an
overestimation due to the information leakage.
According to the recent study that evaluated statistical meth-
odologies used by microarray studies published between 1995
and April 2003, the three papers above were the only ones
that reported both fairly sound crossvalidation analyses and
independent tests (Ntzani and Ioannidis, 2003). Our LTO pro-
cedure includes the validation process of the number of genes
used in the classifier and hence is a complete crossvalidation
process. In addition, the obtained classifier was applied to the
50 independent samples that were measured by the reduced
200 genes system. This is a stronger test than usual indepen-
dent tests but is important for the development of a practical
system at the bedside. In addition, our LTO analysis achieved
an almost unbiased estimation of the accuracy. Our crossvali-
dation analysis using the LTO procedure, the independent test
of the classifier, and the validation of the procedure itself within
a new experimental environment using the mini-chip system
exhibited one of the most conservative and reliable statistical
methodologies. In addition, our gene selection procedure ac-
cording to the pairwise F score tries to extract correlation
structures among genes, based on an idea similar to the ex-
haustive optimization method used in Iizuka et al. (2003), is
beneficial in enhancing the applicability of the mini-chip system
to various prediction problems, namely, short-term and long-
term outcome predictions.
In addition to high accuracy, another advantage of our
method is to provide a type of predictive information beyond
the conventional binary prediction like favorable and unfavor-
able, which is ambiguous. The probabilistic output based on
the hypothetical distribution obtained by the LTO analysis, the
posterior probability, was found to show good accordance with
actual survival rate (right bottom panel in Figure 2); this enables
us to make a simple interpretation of the output: a patient with
a posterior value of 0.8 has 80% chance for the 5 year survival,
for example. Moreover, by calculating posterior probabilities for
various future time points, a survival chance curve for each
patient can be depicted (Figure 6). Although the follow-up
period of patient “S057” is 2 years, and the patient is alive at
this time, the individual survival chance curve says that his/her
survival chance estimated from the gene expression pattern
at diagnosis will get smaller than 50% at about 3 years after
diagnosis. Such an individual survival chance curve can be
used in choosing a suitable therapeutic protocol.
Another advantage of our method is that the probabilistic
output is very stable in the presence of noise. Even when an
artificial noise, whose variance is as large as the estimated
noise variance of microarray, was added to expression profile
data, prognosis prediction did not degrade very much (Figure
S8). This robustness was confirmed when the noise variance
went up to 1.0, which was sufficiently greater than the actual
reproduction noise level of 0.4 (Figures S1A–S1C).345
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ities
LTO estimation of survival probabilities at 0.5, 1.0, 1.5, …, 5.0 years after
diagnosis for 12 typical patients. Left panel: Information of patients (see
caption of Figure 2). Right panel: Estimated posterior probabilities at 0.5,
1.0, 1.5, …, 5.0 years after diagnosis, which predict the time course of pa-
tient’s survival chance. A blue or a red mark denotes that the patient is
alive or dead at that time after diagnosis, respectively. For example, the
patient “S108,” who died at 40 months, is predicted as 100% alive at 0.5
year and 52% alive at 5 year, solely from the microarray analysis at the
diagnosisThe high outcome predictability of our system is attributable
to multiple reasons. The quality of tumor samples is high be-
cause (1) an appropriate system was established for our neuro-
blastoma tissue bank, and (2) handling of tumor tissues is
rather uniform at each hospital, in which informed consent was
obtained. An array, produced by a new apparatus equipped
with a piezo microceramic pump, generates highly reproduc-
ible signals. The noncontact spotting method makes the spot
shape almost a perfect circle. Consequently, the spot excels in
signal uniformity. We did not conduct microdissection of the
136 tumor samples, because the stromal components of the
tumor, e.g., Schwannian cells, are already known to be very
important to characterize its biology (Ambros and Ambros,
1995; Ambros and Ambros, 2000). Therefore, a good combina-
tion or selection of these procedures may have provided high
outcome predictability. In addition, the high predictability was
reliably confirmed by the complete crossvalidation analysis and
the independent test. The probabilistic output based on the
LTO analysis can provide a new type of information that will
improve the therapeutic decision at the bedside. In addition,346the probabilistic output is highly robust against noises that may
be involved in test samples (described above); this can be the
major reason for the high prediction accuracy when the classi-
fier constructed by the 5340 genes system was applied to the
data taken by the mini-chip system.
The impact of the selected genes is strong. The genes with
the highest score in F group genes (F > UF) were tubulin α
members (TUBA3 and K-ALPHA-1, which corresponds to
TUBA1), which have never been reported to be prognostic
factors in neuroblastoma. Their prognostic significance has
also been confirmed by RT-PCR in primary tumors (data not
shown). The high expression of TUBA1 in neuronal cells is as-
sociated with axonal outgrowth during development as well
as with axonal degeneration after axotomy in adult animals
(Knoops and Octave, 1997). The expression of TUBA3 has
been reported to be restricted to adherent, morphologically dif-
ferentiated neuronal and glial cells (Hall and Cowan, 1985). We
have also found that high expression of tubulin tyrosine ligase
and enhanced tubulin tyrosination/detyrosination cycle are as-
sociated with neuronal differentiation in neuroblastomas with
favorable prognosis (Kato et al., 2004). Thus, high mRNA ex-
pression of TUBA genes in favorable neuroblastoma may re-
flect differentiated status of tumors. ARHGEF7, Rho guanine
nucleotide exchange factor 7, activates Rho proteins by ex-
changing bound GDP for GTP and can induce membrane ruf-
fling. In our previous paper, we found that many family mem-
bers of such G protein-related genes are highly expressed in
favorable neuroblastomas compared to unfavorable ones
(Ohira et al., 2003a). This may also imply a neuronal maturity
nature of favorable tumors. Peripherin, a type III intermediate
filament protein, was initially found as a cytoskeletal protein in
the peripheral nervous system and in cultured cells of neuronal
origin. This protein is known to be a marker of terminal neu-
ronal differentiation; however, its functional role in neuro-
blastoma has been elusive. The previous evidence indicates
that peripherin is transcriptionally upregulated by treatment
with NGF, an important neurotrophin in neuroblastoma, and
that the protein product is directly phosphorylated by NGF re-
ceptor, TrkA (Aletta et al., 1989). Thus, peripherin may play an
important role as one of the signal transduction components
involved in elaboration and maintenance of neuronal differenti-
ation. In the UF gene group, many ribosomal protein-related
genes are selected. GNB2L1, a receptor for activated C-kinase
RACK1, is implicated in linking between PKC signaling and ri-
bosome activation (Ceci et al., 2003). The DDX1 gene, which
is frequently coamplified with the MYCN gene in advanced
neuroblastomas (Godbout and Squire, 1993; Noguchi et al.,
1996), is also a member of this group. Its protein product is a
putative RNA helicase and is implicated in a number of cellular
processes involving alteration of RNA secondary structure
such as translation initiation, nuclear and mitochondrial splic-
ing, and ribosome and spliceosome assembly. DDX1 is ranked
at a higher score than the MYCN gene, which is concordant
with the previous reports describing that MYCN mRNA expres-
sion is a weaker prognostic marker than its genomic amplifica-
tion (Slavc et al., 1990). Another important prognostic factor,
TrkA, is not included in the top 70 genes but in the 90 (in the
top 20 genes when the 5 year label was used) (data not
shown), probably due to its relatively low levels of mRNA ex-
pression as compared with those of other genes. The prognos-CANCER CELL : APRIL 2005
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genes which are affected or regulated by TrkA intracellular sig-
naling. Similarly, MYCN-regulated genes such as ribosomal
genes, translation initiation and elongation factors, and laminin
receptor may compensate the effect ofMYCN gene expression
in aggressive tumors. It is intriguing that high mRNA expression
of p53 gene is also strongly related to unfavorable outcome.
Although p53 mutation is rare in primary neuroblastomas, and
its gene product frequently accumulated in cytoplasm, an un-
known mechanism that upregulates p53 expression in aggres-
sive tumors may exist.
Our results showed that the decision by majority by the
genes selected based on microarray data alone can be a prog-
nostic indicator comparative to the existing prognostic mark-
ers, and that the addition of the microarray data to the progno-
sis markers improved the outcome prediction (Table 1). The
outcomes of patients belonging to the intermediate subset,
whose prognosis prediction had been very difficult by existing
prognosis markers, were effectively separated into favorable
group and unfavorable group (p < 10−4). The posterior value
will help the decision of therapeutic modalities, and outcome
prediction based on the posterior value is extremely robust
against a possible noise. In addition, our practical, low-cost
microarray carrying only 200 genes should make its clinical use
possible. Our further validation by hybridizing RNA obtained
from 50 fresh neuroblastomas on the 200 cDNAs microarray in
a completely independent laboratory indicated that our predic-
tion system is consistent and feasible. Therefore, the applica-
tion of a highly qualified cDNA microarray at the bedside may
bring tailored medicine that allows better treatment of neuro-
blastoma patients.
Experimental procedures
Patients and tumor specimens
Fresh, frozen tumor tissues were sent to the Division of Biochemistry, Chiba
Cancer Center Research Institute, from a number of hospitals in Japan
(1996–2002). Informed consent was obtained at each institution or hospital.
We randomly selected tumor samples from this neuroblastoma tissue bank
and then successfully conducted hybridization in 136 neuroblastomas con-
sisting of 41 stage 1 tumors, 22 stage 2 tumors, 33 stage 3 tumors, 28 stage
4 tumors, and 12 stage 4s tumors. Among the 136 fresh neuroblastomas,
seventeen tumors were obtained at the delayed primary surgery after giving
chemotherapy, but the other 119 tumors were resected by biopsy or surgery
without giving any therapy. After surgery, patients were treated according
to the previously described common protocols (Kaneko et al., 1998). Bio-
logical information on each tumor, includingMYCN gene copy number, TrkA
gene expression, and DNA ploidy, was analyzed in our laboratory, as de-
scribed previously (Hishiki et al., 1998). All the tumors were classified ac-
cording to the International Neuroblastoma Staging System (INSS) (Brodeur
et al., 1993). The stage 4s neuroblastoma shows a special pattern of clinical
behaviors, and the tumor itself, as well as its widespread metastases to the
skin, liver, or bone marrow, usually regresses spontaneously. For a better
understanding of statistical results, we introduced Brodeur’s classification
of neuroblastoma subsets: type I (stages 1, 2, or 4s; a single copy ofMYCN;
blue marks in Figure 2), type II (stage 3 or 4; a single copy of MYCN; green
marks in Figure 2), and type III (all stages; amplification ofMYCN; red marks
in Figure 2) (Brodeur and Nakagawara, 1992). Among 136 tumors that we
analyzed, 66 were found by mass screening of urinary catecholamine me-
tabolites at the age of 6 months, which has been performed nationwide in
Japan from 1984 to 2004 (Sawada et al., 1984). The follow-up duration
ranged between 3 and 241 months (median, 56 months; mean, 57.3
months) after diagnosis. All diagnoses of neuroblastoma were confirmed by
the histological assessment of a surgically resected tumor specimen atCANCER CELL : APRIL 2005each hospital. Shimada’s classification (Shimada et al., 1984) was per-
formed in 62 out of 136 cases. The macroscopic necroses in the tumor
were excluded from the tissue sampling for molecular analysis. We used
for the microarray analysis only the tumor samples whose adjacent tissues
contained more than 70% tumor cells in the thin sections stained with he-
matoxylin-eosin. For independent test, 50 (19 were found by mass screen-
ing and 31 were clinically found) tumors (15 of stage 1, 6 of stage 2, 9 of
stage 3, 14 of stage 4, and 6 of stage 4s) were used.
Total RNA was extracted from each frozen tissue according to the AGPC
method (Chomczynski and Sacchi, 1987). RNA integrity, quality, and quan-
tity were then assessed by electrophoresis on the Agilent RNA 6000 na-
nochip using Agilent 2100 BioAnalyzer (Agilent Technologies, Inc.).
cDNA microarray experiments
We previously obtained approximately 5,000 genes after selecting from
10,000 clones randomly picked up from the mixture of oligo-capping cDNA
libraries, which were generated from three primary neuroblastomas with a
favorable outcome (stage 1; high TrkA expression and a single copy of
MYCN), three tumors with a poor prognosis (stage 3 or 4; low expression
of TrkA and amplification of MYCN), and a stage 4s tumor (Ohira et al.,
2003a; Ohira et al., 2003b). Using these isolated genes together with 80
known cDNAs that were thought to be neuroblastoma-related genes, we
first constructed a neuroblastoma proper cDNA microarray (named CCC-
NB5000-Chip) carrying 5340 cDNA spots (the 5340 genes system). Insert
DNAs (average size, approximately 2.5kb) were amplified by polymerase
chain reaction (PCR) from these cDNA clones, purified by ethanol precipita-
tion, and spotted onto a glass slide at a high density with an ink-jet printing
tool (NGK Insulators, Ltd.).
Ten micrograms each of total RNA were labeled with the CyScribe RNA
labeling kit in accordance with the manufacturer’s manual (Amersham Phar-
macia Biotech), followed by probe purification with the Qiagen MinElute
PCR purification kit (Qiagen). We used a mixture of equal amounts of RNA
from each of four neuroblastoma cell lines (NB69, NBL-S, SK-N-AS, and
SH-SY5Y) as a reference. RNAs extracted from primary neuroblastoma tis-
sues and RNAs of the reference mixture were labeled with Cy3 and Cy5
dye, respectively, and were used as probes together with yeast tRNA and
polyA for suppression. Subsequent hybridization and washing were con-
ducted as described previously (Takahashi et al., 2002; Yoshikawa et al.,
2000). Hybridized microarrays were scanned using the Agilent G2505A con-
focal laser scanner (Agilent Technologies, Inc.), and fluorescent intensities
were quantified using the GenePix Pro microarray analysis software (Axon
Instruments, Inc.). The procedure of this study was approved by the Institu-
tional Review Board of the Chiba Cancer Center.
After selecting genes strongly related to the prognosis of patients with
neuroblastoma (at 2 years and at 5 years after diagnosis), we constructed
a 200 cDNAs microarray on glass slides by the same procedure described
above (the mini-chip system). For the independent test using 50 samples,
tumor RNA preparation, probe labeling, and hybridization were conducted
in a completely different laboratory from the original 136 hybridization. In
this independent test, 5 g each of total RNA were used for labeling.
Data preprocessing
To remove chip-wise biases of a microarray system, we used the LOWESS
normalization (Cleveland, 1979). When the Cy3 or Cy5 strength for a clone
was smaller than 3, strength was regarded as abnormally small, and the log
expression ratio of the corresponding clone was treated as a missing value.
The rate of such missing entries was less than 1%. After normalizing the
5340 (genes) by 136 (samples) log expression matrix and removing missing
values, each missing entry was imputed to an estimated value by Bayesian
principal component analysis, which was developed previously (Oba et al.,
2003).
Supervised machine learning and LTO crossvalidation
The 96 samples, whose prognosis at 5 years after diagnosis had been suc-
cessfully checked, were used to train a supervised classifier that predicts
the 5 year prognosis of a new patient. When we considered the short-term
prediction, 126 samples whose 2 year prognosis is known were used. Se-
lection of the genes that are related to the classification is an important
preprocess for reliable prediction. We omitted the genes whose standard347
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smaller than 0.36, so that 1000 genes remained, because the background
noise level was about 0.2–0.3. After the gene screening, the genes were
scored by the pairwise F score, which is a modification of a pairwise corre-
lation method (Bo and Jonassen, 2002), to conduct gene ranking in an at-
tempt not only to obtain higher discrimination accuracy by using a smaller
number of genes but also to reserve the applicability to various outcome
prediction by the set of selected genes (see the Supplemental Data).
We used a well-established technique in the supervised classification
(prognosis prediction), that is, weighted voting with linear discriminators,
where each weight value was calculated as the signal-to-noise ratio (Golub
et al., 1999). In the weighted voting, only n genes with the largest pairwise
F score were used. The number of top genes, n, strongly affects the predic-
tion accuracy (Figure S3) as found in various microarray studies and hence
should be determined such to maximize the leave one out (LOO) crossvali-
dation accuracy. However, a naive determination process of n may intro-
duce information leakage, and the accuracy optimized by the LOO cross-
validation involves overestimation. To avoid such an overestimation, we
consulted a LTO analysis. The LTO analysis was constituted of inner and
outer loops of LOO (Figure S2A); the gene number n was optimized by the
LOO crossvalidation repeating the inner loops, and the optimized classifier
was evaluated by an independent test for a single sample left out at a single
step in the outer loop. During repetition of such steps, the test results of
the outer loop were never fed back to the classifier’s optimization process
in the inner loops, and hence the tests in the outer loop did not include
any overestimation, and the estimated accuracy involved the smallest bias
as possible.
The posterior value for a single sample was calculated based on the dis-
tribution of the weighted vote (decision by majority by the genes that join
the vote) f within the LTO analysis. We regard a real-valued weighted vote
as carrying two kinds of information: its sign predicts the label (favorable or
unfavorable) of the corresponding sample, and its absolute value shows the
prediction strength. The posterior probability p for this sample being favor-
able (alive at 5 years) was evaluated as the logit transformation p = exp(β0
+ β1f)/[1 + exp(β0 + β1f)], where parameters β0 and β1 were estimated by
the maximum likelihood method, in each step in the outer loop of LTO using
the remaining 95 samples and the corresponding labels (5 year prognosis).
Then, the posterior probability of the sample left out in the outer loop was
predicted by the weighted vote f by the classifier constructed in the inner
LOO loops and the parameters β0 and β1 obtained above. There is therefore
no information leakage in this calculation process of the posterior of the
sample left out.
Independent test
Using the 50 independent samples, we performed two kinds of tests. The
first one is an independent test to validate the classifier obtained by our
method and the applicability of our classifier to the mini-chip system, which
has been developed as a clinical tool at the bedside (Figure S2B). According
to the LTO analysis, the supervised classifier was finally constructed by
using all of the 96 training samples measured by the 5340 genes system.
This classifier was evaluated by being directly applied to the 50 samples
measured by the mini-chip system without any information from measure-
ments by the mini-chip system and the 50 test samples. In this test, tumor
RNA preparation, probe labeling, and hybridization were conducted in a
completely different laboratory from that for the 5340 genes system. The
second one is to validate the LTO analysis to construct a supervised classi-
fier by applying the procedure to the data taken by the mini-chip system.
Survival analysis
The Kaplan-Meier survival analysis was also programmed and used to com-
pare patient survival. To assess the association of selected gene expression
with patient clinical outcome, the statistical p and q values were calculated
based on the log rank test.
Immunohistochemistry
Immunostaining with the antibody against peripherin protein (Santa Cruz
Biotechnology; 1:400) was performed on six human neuroblastoma tumors
selected from the surgical pathology file at the Department of Pathology,
Aichi Medical University. They were all neuroblastoma (Schwannian348stroma—poor) and included three favorable histology tumors (poorly dif-
ferentiated subtype without MYCN amplification [one case]; differentiated
subtype withoutMYCN amplification [two cases]) and three unfavorable his-
tology tumors (undifferentiated subtype without MYCN amplification [one
case]; poorly differentiated subtype with MYCN amplification [one case];
poorly differentiated subtype withoutMYCN amplification). All tumor tissues
were obtained prior to chemotherapy and irradiation therapy. Four micron
thick sections from the formalin-fixed, paraffin-embedded samples of these
tumors were treated according to the protocol described previously (Kato
et al., 2004). As for the negative controls, normal goat immunoglobulins
(1:500 dilution; Vector Laboratories) were applied as the primary antibody.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures
and ten supplemental figures and can be found with this article online at
http://www.cancercell.org/cgi/content/full/7/4/337/DC1/.
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